RMC No. 122-2020: VAT-Exempt Drugs List Clarified by FDA Based on Generic Names and Salt Forms

RMC No. 122-2020 clarifies VAT-exempt drug treatment using FDA-listed generic names or INNs, including salt forms, for medicine sellers and buyers. Businesses selling, importing, purchasing, or accounting for medicines covered by the VAT-exempt drug rules must review whether their products fall within the clarified FDA list, because the exemption is determined by the International Non-Proprietary […]

RMC No. 101-2020: Addendum to VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol

RMC No. 101-2020 publishes the FDA addendum to VAT-exempt drugs for hypertension, diabetes, and high cholesterol under RA 11467. Businesses selling, purchasing, prescribing, distributing, or accounting for medicines for hypertension, diabetes, and high cholesterol must immediately check whether their drug databases, point-of-sale systems, invoices, tax coding, and VAT treatment reflect the expanded list of VAT-exempt […]